Premium
Moderate to severe hidradenitis suppurativa treated with biological therapies
Author(s) -
Chinniah Niranthari,
Cains Geoffrey David
Publication year - 2014
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12136
Subject(s) - hidradenitis suppurativa , medicine , proinflammatory cytokine , adalimumab , intensive care medicine , biological drugs , dermatology , disease , immunology , inflammation
Hidradenitis suppurativa is a debilitating disorder that can be difficult to manage with current conventional treatment strategies. Given its association with proinflammatory cytokines there has been interest in the use of novel biological monoclonal antibodies. We describe our experience with the use of these agents in six patients in whom conventional treatment had failed, with promising response noted in some patients. A growing number of studies now highlight the efficacy of these agents.